Linda Fogelstrand

Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

Journal: Trials
Published: February 13, 2026

Deep Sequencing of FLT3-ITD Enables Response Evaluation and Post-Treatment Monitoring in Childhood AML: An Exploratory Study.

Deep Sequencing of FLT3-ITD Enables Response Evaluation and Post-Treatment Monitoring in Childhood AML: An Exploratory Study.

Journal: Pediatric blood & cancer
Published: January 18, 2026

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse.

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse.

Journal: Pediatric blood & cancer
Published: December 10, 2025

Role of MNX1-mediated histone modifications and PBX gene family in MNX1-induced leukemogenesis.

Role of MNX1-mediated histone modifications and PBX gene family in MNX1-induced leukemogenesis.

Journal: Scientific reports
Published: April 18, 2025

Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.

Diagnosis and management of AML in pediatric patients: consensus recommendations from an international expert panel.

Journal: Blood
Published: March 31, 2025

Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation.

Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation.

Journal: Leukemia & lymphoma
Published: March 31, 2025

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel.

Diagnosis and Management of AML in Pediatric Patients: Consensus Recommendations from an International Expert Panel.

Journal: Blood
Published: March 31, 2025

Acute Myeloid Leukemia With NPM1 Mutation Presenting With Rapidly Progressing Hypereosinophilia.

Acute Myeloid Leukemia With NPM1 Mutation Presenting With Rapidly Progressing Hypereosinophilia.

Journal: Case reports in hematology
Published: March 28, 2025

Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study.

Validation of Guidelines for Genetic Investigation of Myeloid Neoplasms with Germline Predisposition: Results from a Prospective Cohort Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 17, 2024

Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.

Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 02, 2024

The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid leukemia through mitochondrial activation.

The proto-oncogenic miR-106a-363 cluster enhances adverse risk acute myeloid leukemia through mitochondrial activation.

Journal: Leukemia
Published: August 30, 2024

The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia.

The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia.

Journal: Nature communications
Published: June 07, 2024
Showing 1-12 of 62

Last Updated: 09/26/2026